An abuse-deterrent, microsphere-in-capsule formulation of extended-release oxycodone: alternative modes of administration to facilitate pain management in patients with dysphagia.
Patients with chronic pain may experience difficulty swallowing, in part due to worsening disease, comorbid conditions, iatrogenic etiology, or age. Patients or caregivers may manipulate extended-release (ER) opioid formulations to facilitate oral dosing due to a lack of therapeutic options that allow for sprinkle or enteral feeding tube administration. If crushed or broken, current oral ER opioids can be associated with adverse sequelae, including risk of potentially fatal overdose.



To review the safety, in vitro dissolution data, and in vivo pharmacokinetic data that support alternative modes of administration of oxycodone DETERx (Xtampza ER) via sprinkling onto soft foods for oral ingestion or via enteral feeding tubes.



A review of oxycodone DETERx data from in vitro and in vivo studies was conducted to demonstrate support for alternative routes and modes of administration.



There was no difference in the dissolution profile when administered with various soft foods or when mixed with various liquid vehicles and administered via nasogastric (NG) or gastrostomy (G) tubes, based on in vitro studies. When sprinkled onto applesauce and administered orally, the microspheres were bioequivalent to the intact oxycodone capsules. When crushed or chewed, the formulation maintained its pharmacokinetic profile; no bolus dose of opioid was released. The sprinkle-dose study was limited by the single-dose study design, as well as the small sample size.



Oxycodone DETERx is the first ER oxycodone formulation that can be administered either intact, sprinkled onto soft foods, or via NG/G tubes, thereby providing options for treating pain in patients who have difficulty swallowing.
a University of California at San Diego School of Medicine , San Diego , CA , USA.
Bill H
BH
McCarberg
b Collegium Pharmaceutical Inc. , Canton , MA , USA.
Ernest A
EA
Kopecky
b Collegium Pharmaceutical Inc. , Canton , MA , USA.
Melinda
M
O'Connor
b Collegium Pharmaceutical Inc. , Canton , MA , USA.
Ann
A
Marseilles
b Collegium Pharmaceutical Inc. , Canton , MA , USA.
Ravi K
RK
Varanasi
b Collegium Pharmaceutical Inc. , Canton , MA , USA.
Christy
C
Thompson
b Collegium Pharmaceutical Inc. , Canton , MA , USA.
Alison B
AB
Fleming
D000284:Administration, Oral; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D059350:Chronic Pain / Q000150:complications / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003680:Deglutition Disorders / Q000150:complications*; D006801:Humans; D010098:Oxycodone / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D059408:Pain Management / Q000379:methods*
D000701:Analgesics, Opioid; D010098:Oxycodone
Abuse-deterrent formulations; Chronic pain; Dysphagia; Extended-release; Opioids